Last reviewed · How we verify
NCT03168997
Memantine Treatment in Alzheimer's Disease Patients
Phase 4 trial testing Memantine Hydrochloride in Alzheimer Disease in 222 participants. Status unknown.
30 September 2018
Quick facts
| Lead sponsor | Wei Cuibai |
|---|---|
| Phase | Phase 4 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 222 |
| Start date | 15 July 2017 |
| Primary completion | 30 September 2018 |
| Estimated completion | 31 December 2018 |
Drugs / interventions tested
- Memantine Hydrochloride — full drug profile →
Conditions studied
- Alzheimer Disease — all drugs for Alzheimer Disease →
Sponsor
Wei Cuibai
Who can join
50 and older, any sex, with Alzheimer Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to investigate whether there will be any efficacy difference of Memantine treatment in different cognitive severity AD patients stratified with BPSD
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Tau-targeting therapies for Alzheimer disease.
Congdon EE, Sigurdsson EM. · · 2018 · cited 838× · PMID 29895964 · DOI 10.1038/s41582-018-0013-z -
Phosphorylated tau targeted small-molecule PROTACs for the treatment of Alzheimer's disease and tauopathies.
Jangampalli Adi P, Reddy PH. · · 2021 · cited 23× · PMID 33940164 · DOI 10.1016/j.bbadis.2021.166162
Verify or expand the search:
- PubMed search for NCT03168997
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Memantine Hydrochloride
Trials testing the same drug.
- NCT06789757 — The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC) · Phase 2 · recruiting
- NCT06337994 — Memantine Hydrochloride for Treatment of Cognitive Dysfunction Due to Traumatic Brain Injury · Phase 3 · completed
- NCT04966546 — Targeting Spreading Depolarization After Chronic Subdural Hematoma Surgery (TASD) · EARLY_PHASE1 · withdrawn
- NCT04939597 — A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor · Phase 3 · active not recruiting
- NCT05531383 — Effect of Early Memantine Administration on Outcome of Patients With Moderate to Severe Traumatic Brain Injury · NA · unknown
Other recruiting trials for Alzheimer Disease
Currently open trials in the same condition.
- NCT07290387 — Tele-Savvy for Latino Caregivers · NA · recruiting
- NCT07178210 — Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease · NA · recruiting
- NCT07294885 — Deep Cervical LymphatIc-Venous Anastomosis for Alzheimer's Disease · NA · recruiting
- NCT06937229 — A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) · Phase 3 · recruiting
- NCT06930560 — HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03168997 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Wei Cuibai
- Last refreshed: 30 May 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03168997.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing